More about Suven Pharmaceuticals Limited
Fundamentals for Suven Pharmaceuticals Limited
Regulatory Filings for Suven Pharmaceuticals Limited
The Hidden Cost of India's Electronics Assembly Push: A 40% E-Waste Surge and the Death of Affordable Repair
The Wedding Loan Trap: How India’s Microfinance Boom Turned Housewives Into Ghost Borrowers and Temple Brass Into EMI Cash
From Lifesaving Drugs to Sick Units: The Hidden Energy Crisis Inside India’s Pharma Clusters
From Price Pressures to Profit Power: The MSME Playbook Redefining India’s Economy
Fundamentals for Suven Pharmaceuticals Limited
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.
Revenue projections:
Suven Pharmaceuticals Limited's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.
Financial Ratios:
| currentRatio | 0.0 |
|---|---|
| forwardPE | 0.0 |
| debtToEquity | 0.0 |
| earningsGrowth | 0.0 |
| revenueGrowth | 0.0 |
| grossMargins | 0.0 |
| operatingMargins | 0.0 |
| trailingEps | 0.0 |
| forwardEps | 0.0 |
Price projections:
Suven Pharmaceuticals Limited's current valuation aligns with projections, revealing no significant risks or opportunities. This stable environment may lead investors to adopt a wait-and-see strategy, monitoring future developments closely.
Recommendation changes over time:
SUVENPHAR has garnered a buy bias from analysts recently, suggesting the stock is a good investment opportunity. This may lead to increased investor interest, as SUVENPHAR is seen as a reliable place to park money for those looking to benefit from potential market gains and company growth.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
₹90 Crore Bet Signals a Massive Shift in India’s Rural Economy
The Hidden Engine of Global Growth: Why India Is Becoming Impossible to Overlook
₹10,000 Crore Deep-Tech Pivot: Why Fund of Funds 2.0 Will Redraw India's Startup Map